Drug Profile
Research programme: cancer and autoimmune disorder imaging agents - ImaginAb/UCLA
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator ImaginAb Inc
- Developer ImaginAb Inc; University of California at Los Angeles
- Class Antibody diagnostics; Imaging agents
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders(Diagnosis) in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA (Parenteral)
- 03 Jun 2014 Preclinical trials in Autoimmune disorders (Diagnosis) in USA (Parenteral)